Contemplate the data and tweets to guess whether the closing price of $bmy will surge or decline at 2017-04-28. Please declare either Rise or Fall.
Context: date,open,high,low,close,adj-close,inc-5,inc-10,inc-15,inc-20,inc-25,inc-30
2017-04-13,0.4,0.7,-0.1,-0.3,-0.3,0.5,1.0,2.3,3.1,4.1,4.6
2017-04-17,-0.4,0.5,-0.8,0.2,0.2,0.1,0.6,1.8,2.6,3.4,4.1
2017-04-18,-0.5,0.4,-0.6,-0.0,-0.0,0.0,0.4,1.5,2.3,3.2,3.9
2017-04-19,-0.4,0.9,-0.6,0.5,0.5,-0.4,-0.2,0.6,1.6,2.5,3.2
2017-04-20,-0.1,0.2,-0.5,0.5,0.5,-0.7,-0.6,-0.1,0.9,1.7,2.6
2017-04-21,-0.1,0.4,-0.6,0.1,0.1,-0.5,-0.6,-0.3,0.7,1.4,2.2
2017-04-24,0.6,0.8,-0.1,0.1,0.1,-0.4,-0.7,-0.5,0.4,1.1,1.8
2017-04-25,-0.5,0.7,-0.5,0.7,0.7,-0.8,-1.3,-1.2,-0.5,0.2,0.9
2017-04-26,0.5,1.6,-0.1,-0.3,-0.3,-0.2,-0.9,-0.9,-0.4,0.4,1.1
2017-04-27,-0.6,0.8,-1.9,3.5,3.5,-2.9,-3.8,-4.0,-3.8,-3.1,-2.4

2017-04-13: #bristolmyerssquibb bristol-myers squibb enters into separate agreements with biogen and roc... read more:  $bmy|#bristolmyerssquibb bristol-myers squibb enters into separate agreements with biogen an
2017-04-14: is now a good time to buy $jpm $esrx $bac $ibm $mpc  $teva $bmy $abbv $hot $v $mdt $axp $dow #ces2018 #ai|is now a good time to buy $jpm $esrx $bac $ibm $mpc  $teva $bmy $abbv $hot $v $mdt $axp $dow #
2017-04-15: rt AT_USER amazing how darzalex $jnj has pulled ahead of empliciti $bmy. here's sellside consensus change over 2 years ($m), via AT_USER|rt AT_USER $bmy makes survival in melanoma combo trial. $mrk, #
2017-04-16: AT_USER could you run a valuation on $nwbo? phase 3 readouts soon and looks incredibly undervalued. possib¡­ | learn 2 trade stocks with jason bond and quit your job [free trial]  $mrk $bmy $xbi $fb $
2017-04-17: $bmy inks news partnership focused on nash |rt AT_USER you get a new r&amp;d head, and you get a new r&amp;d head... $bmy $mack $juno $srpt |bristol-myers squibb $bmy given news sentiment score of 0.1
2017-04-18: healthcare dogs see medical care tops by yield but big pharma tops by gains for april  $abbv $azn $bmy $exetf $gsk|healthcare dogs see medical care tops by yield but big pharma tops by gains for april
2017-04-19: bristol-myers squibb co $bmy insider sells $282,450.00 in stock |#breaking bristol-myers 'holding up better,' but dow's merck still gouging share $bmy $mrk  |rt AT_USER bristol-myers preps 2nd #checkp
2017-04-20: AT_USER AT_USER $bmy and $mrk waiting on topline data in coming weeks from $nwbo  like $cpxx traders wil¡­ |bristol-myers squibb co $bmy shares bought by zurich insurance group ltd fi |bristol-myers s
2017-04-21: rt AT_USER $gild ceo doesn't m/a before earnings, probably will be looking for a new job. $incy $tsro $bmy|is now a good time to buy $jpm $snap $bac $ibm $mpc  $teva $bmy $abbv $hot $v $mdt $axp $dow 
2017-04-22: rt AT_USER new report halves the number of people infected with hepatitis c worldwide | science $gild $bmy $mrk $abbv $rgls |rt AT_USER news from #ilc2017: $bmy¡¯s nash drug reduces liver fat in phase
2017-04-23: AT_USER how about a deal for $bmy or $hain....|AT_USER sounds promising but not sure it'll move the needle on this one. i'm very nervous about the earnings. $bmy|rt AT_USER no more free research/conte
2017-04-24: $bti.v makes a great hire at the ceo position. expect more partnerships to follow. $bmy $mrk $nvs $biib |$bmy's drug cuts liver fat in nash  #easl2017 #ilc2017|rt AT_USER nash - the next untapped phar
2017-04-25: bristol-myers squibb co $bmy now covered by analysts at robert w. baird |analyst activity ¨c robert w. baird initiates coverage on bristol-myers squibb co (nyse:bmy) with a outperform  $bmy|need help 
2017-04-26: unusual options activity - 04.26.2017 - $abx $foxa $bmy $lvs $enlc $vale $x $ea $yndx |rt AT_USER here are the top 25 autoimmune brands in 2016, based on u.s. #pharma sales. $abbv $amgn $jnj $ucb $bmy
2017-04-27: rt AT_USER $bmy - the opdivo number of $1,127m beat consensus which was right around a billion.  |rt AT_USER $bmy: opdivo ahead of expectations. ww: $1.127b vs consensus of $1.031; us $761m versus con
Answer:
Contemplate the data and tweets to guess whether the closing price of $bmy will surge or decline at 2017-04-28. Please declare either Rise or Fall.
Context: date,open,high,low,close,adj-close,inc-5,inc-10,inc-15,inc-20,inc-25,inc-30
2017-04-13,0.4,0.7,-0.1,-0.3,-0.3,0.5,1.0,2.3,3.1,4.1,4.6
2017-04-17,-0.4,0.5,-0.8,0.2,0.2,0.1,0.6,1.8,2.6,3.4,4.1
2017-04-18,-0.5,0.4,-0.6,-0.0,-0.0,0.0,0.4,1.5,2.3,3.2,3.9
2017-04-19,-0.4,0.9,-0.6,0.5,0.5,-0.4,-0.2,0.6,1.6,2.5,3.2
2017-04-20,-0.1,0.2,-0.5,0.5,0.5,-0.7,-0.6,-0.1,0.9,1.7,2.6
2017-04-21,-0.1,0.4,-0.6,0.1,0.1,-0.5,-0.6,-0.3,0.7,1.4,2.2
2017-04-24,0.6,0.8,-0.1,0.1,0.1,-0.4,-0.7,-0.5,0.4,1.1,1.8
2017-04-25,-0.5,0.7,-0.5,0.7,0.7,-0.8,-1.3,-1.2,-0.5,0.2,0.9
2017-04-26,0.5,1.6,-0.1,-0.3,-0.3,-0.2,-0.9,-0.9,-0.4,0.4,1.1
2017-04-27,-0.6,0.8,-1.9,3.5,3.5,-2.9,-3.8,-4.0,-3.8,-3.1,-2.4

2017-04-13: #bristolmyerssquibb bristol-myers squibb enters into separate agreements with biogen and roc... read more:  $bmy|#bristolmyerssquibb bristol-myers squibb enters into separate agreements with biogen an
2017-04-14: is now a good time to buy $jpm $esrx $bac $ibm $mpc  $teva $bmy $abbv $hot $v $mdt $axp $dow #ces2018 #ai|is now a good time to buy $jpm $esrx $bac $ibm $mpc  $teva $bmy $abbv $hot $v $mdt $axp $dow #
2017-04-15: rt AT_USER amazing how darzalex $jnj has pulled ahead of empliciti $bmy. here's sellside consensus change over 2 years ($m), via AT_USER|rt AT_USER $bmy makes survival in melanoma combo trial. $mrk, #
2017-04-16: AT_USER could you run a valuation on $nwbo? phase 3 readouts soon and looks incredibly undervalued. possib¡­ | learn 2 trade stocks with jason bond and quit your job [free trial]  $mrk $bmy $xbi $fb $
2017-04-17: $bmy inks news partnership focused on nash |rt AT_USER you get a new r&amp;d head, and you get a new r&amp;d head... $bmy $mack $juno $srpt |bristol-myers squibb $bmy given news sentiment score of 0.1
2017-04-18: healthcare dogs see medical care tops by yield but big pharma tops by gains for april  $abbv $azn $bmy $exetf $gsk|healthcare dogs see medical care tops by yield but big pharma tops by gains for april
2017-04-19: bristol-myers squibb co $bmy insider sells $282,450.00 in stock |#breaking bristol-myers 'holding up better,' but dow's merck still gouging share $bmy $mrk  |rt AT_USER bristol-myers preps 2nd #checkp
2017-04-20: AT_USER AT_USER $bmy and $mrk waiting on topline data in coming weeks from $nwbo  like $cpxx traders wil¡­ |bristol-myers squibb co $bmy shares bought by zurich insurance group ltd fi |bristol-myers s
2017-04-21: rt AT_USER $gild ceo doesn't m/a before earnings, probably will be looking for a new job. $incy $tsro $bmy|is now a good time to buy $jpm $snap $bac $ibm $mpc  $teva $bmy $abbv $hot $v $mdt $axp $dow 
2017-04-22: rt AT_USER new report halves the number of people infected with hepatitis c worldwide | science $gild $bmy $mrk $abbv $rgls |rt AT_USER news from #ilc2017: $bmy¡¯s nash drug reduces liver fat in phase
2017-04-23: AT_USER how about a deal for $bmy or $hain....|AT_USER sounds promising but not sure it'll move the needle on this one. i'm very nervous about the earnings. $bmy|rt AT_USER no more free research/conte
2017-04-24: $bti.v makes a great hire at the ceo position. expect more partnerships to follow. $bmy $mrk $nvs $biib |$bmy's drug cuts liver fat in nash  #easl2017 #ilc2017|rt AT_USER nash - the next untapped phar
2017-04-25: bristol-myers squibb co $bmy now covered by analysts at robert w. baird |analyst activity ¨c robert w. baird initiates coverage on bristol-myers squibb co (nyse:bmy) with a outperform  $bmy|need help 
2017-04-26: unusual options activity - 04.26.2017 - $abx $foxa $bmy $lvs $enlc $vale $x $ea $yndx |rt AT_USER here are the top 25 autoimmune brands in 2016, based on u.s. #pharma sales. $abbv $amgn $jnj $ucb $bmy
2017-04-27: rt AT_USER $bmy - the opdivo number of $1,127m beat consensus which was right around a billion.  |rt AT_USER $bmy: opdivo ahead of expectations. ww: $1.127b vs consensus of $1.031; us $761m versus con
Answer:+Rise